PORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive OfficerPORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer

FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference

PORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive Officer, Dr. Werner Lanthaler, will present at the J.P. Morgan 2026 Healthcare Conference, taking place from January 12 – 15, 2026 in San Francisco, CA.

With more than a decade of expertise, FJBio has supported over 250 clients across Pharma, Biotech and Academia and contributed to more than 19 antibodies advancing to clinical stage development or the market. During his presentation, Dr. Lanthaler will address FJBio’s strategic positioning as a highly efficient, integrated partner. He will showcase the Company’s antibody discovery and development solutions, with a focus on innovation, data-driven platforms and scalable collaboration models across the biopharmaceutical ecosystem.

Presenter

Role

Date

Time

Venue

Dr. Werner Lanthaler

CEO, FJBio

Jan 13

09:00–09:25 AM

“Golden Gate” at THE WESTIN, 32nd floor

In addition to the CEO presentation, members of FJBio’s Senior Management and Business Development teams will attend the conference for strategic discussions with representatives of global pharmaceutical companies, biotechnology innovators and other industry partners throughout the event.

Dr. Werner Lanthaler, Chief Executive Officer of FairJourney Bio, commented: “I look forward to presenting FairJourney Bio’s unique platform for partnered pipeline building at this year’s J.P. Morgan 2026 Healthcare Conference. This conference brings together a highly curated group of global healthcare leaders and innovators and I appreciate the opportunity to engage in meaningful dialogue around the future of efficient, data-enabled antibody discovery and development.”

Participation as a presenting company at this conference is highly selective and considered a significant distinction, reflecting FJBio’s growing global recognition and relevance within the international life sciences community. The conference provides an important platform for FJBio to strengthen existing relationships, explore new strategic partnerships and further position the Company as a trusted global partner across the full value chain.

Contacts

FairJourney Biologics
Hinnerk Rohwedder

Head of Marketing & Communications

hrohwedder@fjbio.com

Zyme Communications

Lily Jeffery
Email: lily.jeffery@zymecommunications.com
Tel: +44 (0)7891 477 378

Market Opportunity
BIO Protocol Logo
BIO Protocol Price(BIO)
$0.04996
$0.04996$0.04996
-1.14%
USD
BIO Protocol (BIO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Aave CEO Breaks Silence on Game-changing Upgrade in Q4: Details

Aave CEO Breaks Silence on Game-changing Upgrade in Q4: Details

The post Aave CEO Breaks Silence on Game-changing Upgrade in Q4: Details appeared on BitcoinEthereumNews.com. Aave CEO and founder Stani Kulechov has broken his silence on a major upgrade coming to Aave in Q4, 2025. The Aave v4 upgrade is anticipated to be one of the major events in DeFi in 2025, including features such as a Hub-and-Spoke architecture, reinvestment module and others, boosting Aave liquidity and saving gas. The upgrade will also include UX improvements and a new liquidation engine. The Reinvestment Module would help Aave earn more from unused capital, utilizing idle liquidity. On Sept. 15, the Aave founder informed the crypto community of the Aave v4 upgrade roadmap, which highlights where the project is currently at in its development. Aave CEO reacts The Aave founder commented in reaction to a tweet highlighting the features of Aave V4, “very nice overview of the Aave V4 feature,” adding that the Reinvestment Module was not part of the initial design. Very nice overview of the Aave V4 features. Interestingly, the Reinvestment Module wasn’t part of our original design a couple of years ago when we laid down the protocol architecture. It actually emerged later as an unexpected, but exciting, “last-minute” addition. The… https://t.co/Zkp3bmrCAZ — Stani.eth (@StaniKulechov) September 17, 2025 “Interestingly, the Reinvestment Module wasn’t part of our original design a couple of years ago when we laid down the protocol architecture. It actually emerged later as an unexpected, but exciting, last-minute addition,” Kulechov added. The Aave CEO explained the reinvestment feature further as one that allows the protocol to deploy pool float into low-risk, highly liquid yield strategies, creating additional efficiency for LPs. The feature is somewhat inspired by Ethena’s rebalance to USDtb but applied natively within Aave. The Aave team shared the launch roadmap for the Aave upgrade on Sept. 15, revealing a recent V4 Development Update. Source: https://u.today/aave-ceo-breaks-silence-on-game-changing-upgrade-in-q4-details
Share
BitcoinEthereumNews2025/09/18 16:57
X3 Acquisition Corp. Ltd. Announces Closing of $200,000,000 Initial Public Offering

X3 Acquisition Corp. Ltd. Announces Closing of $200,000,000 Initial Public Offering

MINNEAPOLIS–(BUSINESS WIRE)–X3 Acquisition Corp. Ltd. (Nasdaq: XCBEU) (the “Company”), a newly organized special purpose acquisition company formed as a Cayman
Share
AI Journal2026/01/23 05:46
North America’s Largest RV Dealers Still Failing Google Core Web Vitals–Overfuel Reports Nearly 79% Failure Rate for Second Year

North America’s Largest RV Dealers Still Failing Google Core Web Vitals–Overfuel Reports Nearly 79% Failure Rate for Second Year

INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ — Overfuel, a website solutions provider for automotive, powersports and RV dealers, today announced the findings of its
Share
AI Journal2026/01/23 05:15